DIN 02467224 — OCREVUS 30 MG
OCREVUS is a solution of Ocrelizumab marketed by HOFFMANN-LA ROCHE LIMITED. The full Ocrelizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02467224
- Brand name
- OCREVUS
- Active ingredient
- Ocrelizumab
- Strength
- 30 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- HOFFMANN-LA ROCHE LIMITED
- Health Canada status
- MARKETED
- Drug class
- Anti-CD20 monoclonal antibody (selective immunomodulator)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.